Corteva Inc (CTVA) Stock Forecast & Price Target

Corteva is supported by a strong crop protection franchise, a robust pipeline of new active ingredients, and a biologics portfolio that together can offset legacy product pressure and drive earnings growth as farmer economics improve. Shares appear attractive at roughly 6.5x to 6.7x EV/EBITDA on 2027E and about a 10% unlevered FCF yield, while the balance sheet is expected to end 2026 with a $0.5B net cash position and more than $1.5B available for buybacks and M&A. Management’s cost actions, including another $200M of savings, plus potential sales uplift of about $1B by 2029 from new products and biologics, support EBITDA toward the top end of the $1.45B-$1.65B range.

Corteva is facing a fundamentally challenged crop chemicals backdrop, with limited volume growth, persistent generic-driven deflation, and management itself assuming a 1% annual price decline during the 2027-2029 period. Weak farm economics and softer crop prices could further pressure spending on crop protection, while the company expects continued pricing pressure in CP and only low-single-digit seed volume improvement in 2026. Its narrower post-spin portfolio may also weaken its leverage with large customers, especially in Brazil, where roughly 25% of the route to market is direct to large farms, and downside scenarios already point to EBITDA of $4,350M.